Medicenna Therapeutics Corp turning Bullish
COMPANY PROFILE
Medicenna Therapeutics Corp. is a clinical stage immunotherapy company, which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
AVERAGE ANALYSTS PRICE TARGET $3.30
AVERAGE ANALYSTS RECOMMENDATION buy
Medicenna Therapeutics Corp. is a clinical stage immunotherapy company, which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
AVERAGE ANALYSTS PRICE TARGET $3.30
AVERAGE ANALYSTS RECOMMENDATION buy